Thipparat SuwanmaneeHalin SierakowskaGiuseppina LacerraSaovaros SvastiSuzanne KirbyChristopher E. WalshSuthat FucharoenRyszard KoleThe University of North Carolina at Chapel HillMahidol University2018-07-242018-07-242002-09-01Molecular Pharmacology. Vol.62, No.3 (2002), 545-5530026895X2-s2.0-0036765860https://repository.li.mahidol.ac.th/handle/20.500.14594/20047Correct human β-globin mRNA has been restored in erythroid cells from transgenic mice carrying the human gene with β-globin IVS2-654 splice mutation and from thalassemia patients with the IVS2-654/βE genotype. This was accomplished in a dose- and time-dependent manner by free uptake of morpholino oligonucleotide antisense to the aberrant splice site at position 652 of intron 2 in β-globin pre-mRNA. Under optimal conditions of oligonucleotide uptake, the maximal levels of correct human β-globin mRNA and hemoglobin A in patients' erythroid cells were 77 and 54%, respectively. These levels of correction were equal to, if not higher than, those obtained by syringe loading of the oligonucleotide into the cells. Comparison of splicing correction results with the cellular uptake of fluorescein-labeled oligonucleotide indicated that the levels of mRNA and hemoglobin A correlate well with the nuclear localization of the oligonucleotide and the degree of erythroid differentiation of cultured cells. Similar but not as pronounced results were obtained after the oligonucleotide treatment of bone marrow cells from IVS2-654 mouse. The effectiveness of the free antisense morpholino oligonucleotide in restoration of correct splicing of IVS2-654 pre-mRNA in cultured erythropoietic cells from transgenic mice and thalassemic patients suggests the applicability of this or similar compounds in in vivo experiments and possibly in treatment of thalassemia.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1124/mol.62.3.545